What problem are we trying to solve?

  • Without a steady supply of talent, innovation in outcome-based cardiovascular drug/device development is at risk.
  • Currently, there are only limited opportunities, if any, for clinical academics to gain expertise in the conduct of these global trials.


What Can the Fellowship Offer?

  • Work with Executive/Steering Committees and clinician scientists in Boehringer Ingelheim on CV outcome trial(s).
  • Undertake analyses of datasets that complements the fellow’s interest.


Why Boehringer Ingelheim?

  • Boehringer Ingelheim has a strong legacy of cardiovascular outcome trials, including EMPA-REG OUTCOME trial.
  • As a family-owned company, Boehringer Ingelheim plans in generations.
  • This partnership with CVCT is a unique opportunity to nurture future leaders in cardiovascular medicine.


How can I (or my colleague) apply?

Please contact the chairs of CVCT

  • Pr Faiez Zannad
  • Dr Bertram Pitt